Navigation Links
Isogen Retains Strategic Partner Sheridan Road Financial to Meet Global Biopharma Demand
Date:12/3/2008

NEWARK, Del., Dec. 3 /PRNewswire/ -- Isogen, a contract development and manufacturing organization for sterile filling, announced it has retained a strategic financial partner to help it expand operations to meet the global biopharma demand for Isogen's services.

Isogen has previously announced a successful first round series of capital investment and the opening of its first filling line facility in Q1 2009 to deliver on the previously unmet process, facility and capacity needs of the $2 billion highly-niched, low-volume clinical and early-stage commercial sterile filling market segment.

Pharmaceutical companies can invest over $100 million and four years to develop sterile manufacturing capacity, but are highly reluctant to take this initiative until they are certain the candidate drug will receive regulatory approval. Isogen will set a new industry standard for GMP-compliant clinical manufacturing and containment, enabling Isogen's customers to plan and execute the supply of integrated sterile clinical and small scale commercial launches of single or multiple therapeutics at the same time while dramatically reducing costs and risks that are inherently associated with other in-house and outsourced alternatives.

"Our initial-stage private financing, Delaware state government backing and follow-on funding will enable Isogen to be the best positioned firm to meet the pent-up demand in biopharma for the unmet contract filling, containment and quality standards, while significantly reducing sterile manufacturing capital costs and time-to-market for new drugs," said Les Edwards, CEO, Isogen.

Biopharma's existing paradigm of spending hundreds of millions of dollars and waiting years to build additional sterile filling capacity to address clinical and commercial capacity needs of large pipelines no longer remains a viable option. Firms have few options to address these issues, and each solution presents significant drawbacks. Building new commercial sterile filling lines for clinical fills in-house is cost prohibitive. Large contract fillers have no financial incentive to service clinical volume-size projects, while small specialist clinical fillers lack the necessary expertise and equipment to adequately deliver against a pharmaceutical company's complex needs. As a result, Isogen is the best positioned company on the market to address these unmet needs. Sheridan Road Financial will provide a path by which Isogen can ramp follow-on funding to expand its presence in the biopharma industry.

"Isogen will help our customers address major industry dynamics that are reshaping the face and complexity of sterile clinical trials materials supply," said Edwards. "Regulators in the U.S. and Europe increasingly require sterile clinical trials supplies to be manufactured in accordance with current Good Manufacturing Practice (cGMP) standards. At the same time many new pipeline drugs moving into clinical trials are potent compounds and require Isogen's unique barrier isolation containment technology. Our process ensures safe manufacturing, while meeting strict global regulatory standards," Edwards concluded.

About Sheridan Road

Sheridan Road provides independent strategic senior level corporate finance and mergers and acquisition advisory services to its clients. Sheridan Road is also one of the largest advisors of corporate 401(k) plans in the country and has been widely regarded as an industry leader in the space. The firm also provides comprehensive wealth management services to executives and family offices.

About Isogen

Isogen is the leader in advanced sterile manufacturing for potent and non-potent therapeutics for the critical clinical/commercial scale manufacturing transition. Isogen provides a fully integrated suite of services including formulation, technology transfer and validation services for the contract filling of liquids and lyophilized formulations for vaccines, monoclonal antibodies and other synthetic and biologically derived therapeutics. Isogen delivers critical full service resources to pharmaceutical and biopharmaceutical manufacturers seeking solutions in advanced sterile filling including clinical and transitional contract filling, formulation/validation based analytical laboratory services and advanced sterile fill line/equipment design and GMP project management. For more information, contact Joe Romano, Partner, HighGround at +1-781-939-5800 x 208 or jromano@highgroundinc.com


'/>"/>
SOURCE Isogen
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Isogen Launches Major New Facility to Address Global Biopharma Demand
2. CSL Behring Study in Animal Models Shows Feasibility of Developing a Half-Life Extended Recombinant FVIIa that Retains Biologic Activity
3. Vermillion Renews Strategic Alliance Agreement With Quest Diagnostics, Inc.
4. Encorium Announces the Initiation of a Strategic Partnership With Prologue Research After the Postponement of Negotiations Regarding Its Planned Acquisition; Strategic Reorganization and Cost Reduction Plan Initiated as Strategic Alternatives are Investig
5. TorreyPines Therapeutics Announces Strategic Plan with Focus on Clinical Development Activities to Maximize Value of Versatile Lead Compounds
6. IDM Pharma Provides Update of Product Pipeline and Announces Plans to Evaluate Strategic Alternatives for the Company
7. Replidyne Provides Strategic Update
8. StatSure Signs Strategic Financing and License Deals with Inverness Medical Innovations
9. Strategic Diagnostics Launches Initial Oncology-Targeted Antibody Reagent Catalog
10. General Wesley Clark Joins Immtech as Consulting Strategic Advisor
11. ASGE and The Pancreatic Cancer Action Network Partner to Raise Awareness About Pancreatic Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/4/2016)... 2016 Wegener Polyangiitis - Pipeline Review, ... ,Wegener Polyangiitis - Pipeline Review, H2 2015, provides ... This report provides comprehensive information on the ... analysis at various stages, therapeutics assessment by drug ... (RoA) and molecule type, along with latest updates, ...
(Date:2/4/2016)... Summary Breast cancer, a malignant neoplasm, ... common cancer in women worldwide, accounting for 16% of ... number of women diagnosed with breast cancer has increased ... deaths has declined due to earlier diagnosis and better ... in the past four decades, especially with increasing usage ...
(Date:2/4/2016)... LONDON , Feb. 4, 2016 ... Identifying and Commercializing First-in-Class Innovation ... disorder associated with chronic inflammation of the airways ... of COPD symptoms make the disease one of ... cause of death in the world. COPD is ...
Breaking Medicine Technology:
(Date:2/6/2016)... ... February 06, 2016 , ... US Sports Camps is proud to sponsor the ... brings together top non-profit leaders, ultimate organizations, and coaches from around the US. The ... Area Disc Program Director of Youth and Education, describes this year YUCC as “an ...
(Date:2/5/2016)... ... February 05, 2016 , ... Love is in the air at King ... colors, assortments and packaging. This staple for Valentine’s Day is a must-have, and can ... For Valentine’s Day, not only are long-stem roses available, but also other flower bouquets, ...
(Date:2/5/2016)... , ... February 05, 2016 , ... ... domestic franchisees of Popeyes Louisiana Kitchen restaurants, launched the 14th annual “Appetite for ... kids and adults with muscular dystrophy, ALS and related diseases that severely limit ...
(Date:2/5/2016)... , ... February 05, 2016 , ... ... devoted exclusively to funding innovative lymphoma research and serving the lymphoma community through ... poised to once again host, Swirl, A Wine Tasting Event at the La ...
(Date:2/5/2016)... ... 2016 , ... Give To Cure today announced that it is ... Give To Cure’s campaign that is crowdfunding clinical trials to help find cures faster ... through a smart device. In 2015 alone, Venmo processed $7.5 billion in transactions among ...
Breaking Medicine News(10 mins):